MXPA03000428A - Derivados de tetrahidro-heterociclo-acepinil-pirimidina. - Google Patents

Derivados de tetrahidro-heterociclo-acepinil-pirimidina.

Info

Publication number
MXPA03000428A
MXPA03000428A MXPA03000428A MXPA03000428A MXPA03000428A MX PA03000428 A MXPA03000428 A MX PA03000428A MX PA03000428 A MXPA03000428 A MX PA03000428A MX PA03000428 A MXPA03000428 A MX PA03000428A MX PA03000428 A MXPA03000428 A MX PA03000428A
Authority
MX
Mexico
Prior art keywords
compounds
tetrahydro
pyrimidine derivatives
heterocycloazepinyl
heterocycloazepinyl pyrimidine
Prior art date
Application number
MXPA03000428A
Other languages
English (en)
Spanish (es)
Inventor
Vincent Mutel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA03000428A publication Critical patent/MXPA03000428A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
MXPA03000428A 2000-07-18 2001-07-16 Derivados de tetrahidro-heterociclo-acepinil-pirimidina. MXPA03000428A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00115450 2000-07-18
PCT/EP2001/008186 WO2002006288A1 (en) 2000-07-18 2001-07-16 Tetrahydro-heterocycloazepinyl pyrimidine derivatives

Publications (1)

Publication Number Publication Date
MXPA03000428A true MXPA03000428A (es) 2003-06-24

Family

ID=8169290

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03000428A MXPA03000428A (es) 2000-07-18 2001-07-16 Derivados de tetrahidro-heterociclo-acepinil-pirimidina.

Country Status (17)

Country Link
US (1) US6369222B1 (cg-RX-API-DMAC7.html)
EP (1) EP1303521B1 (cg-RX-API-DMAC7.html)
JP (1) JP4060705B2 (cg-RX-API-DMAC7.html)
KR (1) KR100525214B1 (cg-RX-API-DMAC7.html)
CN (1) CN1187358C (cg-RX-API-DMAC7.html)
AR (1) AR031715A1 (cg-RX-API-DMAC7.html)
AT (1) ATE288437T1 (cg-RX-API-DMAC7.html)
AU (2) AU2002210418B2 (cg-RX-API-DMAC7.html)
BR (1) BR0112586A (cg-RX-API-DMAC7.html)
CA (1) CA2415966C (cg-RX-API-DMAC7.html)
DE (1) DE60108759T2 (cg-RX-API-DMAC7.html)
DK (1) DK1303521T3 (cg-RX-API-DMAC7.html)
ES (1) ES2236317T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA03000428A (cg-RX-API-DMAC7.html)
PT (1) PT1303521E (cg-RX-API-DMAC7.html)
WO (1) WO2002006288A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200300163B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074549B1 (en) * 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
US20040215284A1 (en) * 2003-01-30 2004-10-28 Recordati S.A. Treatment of neuromuscular dysfunction of the lower urinary tract with selective mGlu5 antagonists
DE10320785A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
DE10328479A1 (de) 2003-06-25 2005-01-13 Bayer Ag 6-Arylamino-5-cyano-4-pyrimidinone
DE102004001873A1 (de) 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
DE102004019708A1 (de) * 2004-04-20 2005-11-17 Basf Ag Offenzellige Schaumstoffe und Verfahren zu ihrer Herstellung
US7718647B2 (en) * 2004-06-30 2010-05-18 Athersys, Inc. Substituted azepine derivatives as serotonin receptor modulators
JP5002460B2 (ja) 2004-10-04 2012-08-15 ミレニアム ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼインヒビターとして有用なラクタム化合物
WO2007072095A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. New compounds
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
JP5412430B2 (ja) * 2007-08-02 2014-02-12 レコルダーティ アイルランド リミテッド ｍＧｌｕ５拮抗薬としての新規複素環系化合物
EP2217602B1 (en) 2007-11-30 2018-08-29 Boehringer Ingelheim International GmbH 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders
PE20091102A1 (es) 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
US9079905B2 (en) 2008-09-08 2015-07-14 Boehringer Ingelheim International Gmbh Compounds for the treatment of CNS disorders
EP2373657B1 (en) 2008-12-05 2016-09-14 Millennium Pharmaceuticals, Inc. 5,7-dihydro-6h-pyrimido[5,4-d][1]benzazepin-6-thiones as plk inhibitors
WO2010089119A1 (en) 2009-02-04 2010-08-12 Recordati Ireland Limited Heterocyclic derivatives as m-glu5 antagonists
MA33152B1 (fr) 2009-03-31 2012-03-01 Boehringer Ingelheim Int Dérivés 1-hétérocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a
EP2477981A1 (en) 2009-09-14 2012-07-25 Recordati Ireland Limited Heterocyclic mglu5 antagonists
PH12012502348A1 (en) * 2010-07-09 2022-10-24 Recordati Ireland Ltd Novel spiroheterocyclic compounds as mglu5 antagonists
MY170189A (en) 2010-08-12 2019-07-09 Boehringer Ingelheim Int 6-cycloalkyl-1, 5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) * 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940395A (en) * 1969-08-29 1976-02-24 American Home Products Corporation 4-Amino-2-phenyl-6-thiopryimidines
BG17785A3 (bg) * 1970-08-14 1973-12-25 Dr. Karl Thomae Gmbh Метод за получаване на нови азетинови производни
BE790287A (fr) * 1971-10-28 1973-04-19 Delalande Sa Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique
FR2608607B1 (fr) 1986-12-23 1989-04-28 Sanofi Sa Procede de preparation de thienylethylamines et dithienylethylamines ainsi obtenues
DE3820775A1 (de) 1988-06-20 1989-12-21 Thomae Gmbh Dr K Neue 4,5,7,8-tetrahydro-6h-thiazolo(5,4,-d)azepine, ihre herstellung und ihre verwendung als arzneimittel
US5444062A (en) * 1990-11-06 1995-08-22 Pfizer Inc. Quinazolines derivatives for enhancing antitumor activity

Also Published As

Publication number Publication date
BR0112586A (pt) 2003-05-20
ZA200300163B (en) 2004-04-07
US6369222B1 (en) 2002-04-09
DK1303521T3 (da) 2005-06-13
PT1303521E (pt) 2005-05-31
AU1041802A (en) 2002-01-30
AR031715A1 (es) 2003-10-01
CN1187358C (zh) 2005-02-02
JP2004504324A (ja) 2004-02-12
ES2236317T3 (es) 2005-07-16
US20020045635A1 (en) 2002-04-18
CA2415966C (en) 2009-10-27
AU2002210418B2 (en) 2006-08-17
CA2415966A1 (en) 2002-01-24
EP1303521B1 (en) 2005-02-02
KR20030015397A (ko) 2003-02-20
KR100525214B1 (ko) 2005-11-01
DE60108759T2 (de) 2006-05-11
ATE288437T1 (de) 2005-02-15
WO2002006288A1 (en) 2002-01-24
DE60108759D1 (de) 2005-03-10
EP1303521A1 (en) 2003-04-23
JP4060705B2 (ja) 2008-03-12
CN1441804A (zh) 2003-09-10

Similar Documents

Publication Publication Date Title
MXPA03000428A (es) Derivados de tetrahidro-heterociclo-acepinil-pirimidina.
MXPA03010822A (es) Derivados de pirimidina, triazina y pirazina como receptores de glutamato.
JO2285B1 (en) Dihydro-benzoic derivatives
MXPA03010810A (es) Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos.
JO2273B1 (en) Dihydro-benzo derivatives [B] [1.4] di-azin-2-one
MY176608A (en) Dihydrobenzodiazepin-2-one derivatives iii
TWI265928B (en) A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
EP1277754B8 (en) Imidazopyridine derivatives
WO2004065392A8 (en) Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
GEP20125691B (en) Compounds and compositions as protein kinase inhibitors
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
YU11501A (sh) Derivati 4,4,-biarilpiperidina sa aktivnošću na receptor opijata
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
NO20080563L (no) Pyrazol[3,4-d]azepinderivater som histamin H3 antagonister
TW200509920A (en) Imidazole derivatives
EP1142881A4 (en) POLY (ADP-RIBOSE) POLYMERASE INHIBITORS CONSISTING OF PYRIMIDINE DERIVATIVES
IL191748A0 (en) 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
IL161842A (en) 2-amino-4-heteroarylethyl-thiazoline derivatives and pharmaceutical compositions comprising them
MXPA05011163A (es) Derivados de 3-benzhidriliden-8-azabiciclo[3.2.1]octano con actividad de receptores opioides.
MXPA05013233A (es) Derivados de imidazol heteroaril-substituidos como antagonistas del receptor de glutamato.
WO2004004725A3 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases

Legal Events

Date Code Title Description
FG Grant or registration